Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy
Advanced Healthcare Materials · 2024-05 · 13 (13)
DOI: 10.1002/adhm.202400068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 15.02.2024. Verfasst von Yuanwei Pan und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Research and Application Center of Precision Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450014, China. Hauptthemen laut MEDLINE: Immunotherapy, Cancer Vaccines, Dendritic Cells. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Shenzhen Medical Research Fund.
Abstract (Originalsprache)
Cancer nanovaccines have attracted widespread attention by inducing potent cytotoxic T cell responses to improve immune checkpoint blockade (ICB) therapy, while the lack of co‐stimulatory molecules limits their clinical applications. Here, a genetically engineered cancer cytomembrane nanovaccine is reported that simultaneously overexpresses co‐stimulatory molecule CD40L and immune checkpoint inhibitor PD1 to elicit robust antitumor immunity for cancer immunotherapy. The CD40L and tumor antigens inherited from cancer cytomembranes effectively stimulate dendritic cell (DC)‐mediated immune activation of cytotoxic T cells, while the PD1 on cancer cytomembranes significantly blocks PD1/PD‐L1 signaling pathway, synergistically stimulating antitumor immune responses. Benefiting from the targeting ability of cancer cytomembranes, this nanovaccines formula shows an enhanced lymph node trafficking and retention. Compared with original cancer cytomembranes, this genetically engineered nanovaccine induces twofold DC maturation and shows satisfactory precaution efficacy in a breast tumor mouse model. This genetically engineered cytomembrane nanovaccine offers a simple, safe, and robust strategy by incorporating cytomembrane components and co‐stimulatory molecules for enhanced cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Research and Application Center of Precision Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450014, China.
- Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen, 518132, China.
- Key Laboratory of Artificial Micro- and Nano-Structures of Ministry of Education, School of Physics and Technology, Wuhan University, Wuhan, 430072, China.
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China.
- The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
ORCID-Profile: Lang Rao
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Shenzhen Medical Research Fund
- Shenzhen Science and Technology Program
- Shenzhen Bay Laboratory Proof-of-Concept Fund
- Shenzhen Bay Laboratory Startup Fund
Zitieren
APA
Pan, Y., Wu, X., Liu, L., Zhao, C., Zhang, J., Yang, S., Pan, P., Huang, Q., Zhao, X. Z., Tian, R., & Rao, L. (2024). Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy. Advanced Healthcare Materials, 13(13). https://doi.org/10.1002/adhm.202400068
Vancouver
Pan Y, Wu X, Liu L, Zhao C, Zhang J, Yang S, et al. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy. Advanced Healthcare Materials. 2024;13(13). doi:10.1002/adhm.202400068
BibTeX
@article{Pan2024,
author = {Pan, Yuanwei and Wu, Xianjia and Liu, Lujie and Zhao, Chenchen and Zhang, Jing and Yang, Shengren and Pan, Pan and Huang, Qinqin and Zhao, Xing-Zhong and Tian, Rui and Rao, Lang},
title = {Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {13},
doi = {10.1002/adhm.202400068}
}
EUVIMED